FITC-Labeled Human Her2 / ErbB2 Protein, His Tag

Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2, HER-2 /neu, NEU, NGL, TKR1 and c-erb B2, and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 70.2 kDa. The protein migrates as 80-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized Trastuzumab at 0.5 μg/mL (100 μL/well) can bind FITC-Labeled Human Her2, His Tag (Cat. No. HE2-HF224) with a linear range of 0.02-0.313 μg/mL (QC tested).